Current News

Exclusive Distributor Appointed for Denmark and Sweden

Melbourne, Australia, 25 September 2017: Sienna Cancer Diagnostics, a commercial stage, medical ..Read More

Appendix 4E & 2017 Financial Report Release

Sienna has released its Appendix 4E and Financial Report for the period ended 30 June 2017. Thes..Read More

Sienna Cancer Diagnostics (ASX:SDX) Lists On ASX

Highlights: Sienna Cancer Diagnostics has listed on the Australian Securities Exchange (ASX)..Read More

Sienna Raises $4.6m From IPO

Highlights: Sienna raised $4.6 million, adding approximately 470 new shareholders to the Com..Read More

Sienna IPO Closing July 17th

Sienna’s Initial Public Offering (IPO) to raise up to $6M through the issuance of up to 30 mil..Read More

Sienna Seeks Listing on ASX with IPO

Sienna has applied to the ASX for listing on the Australian Stock Exchange. The company plan..Read More

Resources Added to Drive Key Strategies

Sienna has added two key resources to the business to enable planning and execution of key strategie..Read More

New CEO Appointed From Within Sienna

Sienna Cancer Diagnostics Ltd today announced the Board’s decision to appoint Matthew Hoskin t..Read More

Successful Capital Raise Completed

The Board and management of Sienna are pleased to announce the company has raised approximately ..Read More

TGA Lists Sienna's IVD Product For Sale in Australia

Sienna has completed its third major regulatory milestone for the quarter, receiving Therapeutic..Read More

Sienna Registers CE Marked IVD Product in EU

Following on from their recent registration with the FDA in the United States, Sienna has now regist..Read More

Sienna Appoints Swiss Distribution Partner

Sienna Cancer Diagnostics Ltd. and Biosystems Switzerland AG have entered an exclusive distribution ..Read More

FDA Registration For Sienna - First IVD Product Listing

Sienna Cancer Diagnostics has listed an in-vitro diagnostic (IVD) medical device with the United Sta..Read More

Sienna Receives ISO13485 Certification

Sienna have received formal certification that their Quality Management System complies with the..Read More

Sienna Receives $638K in R&D Tax Incentive Funding

Sienna today reported the receipt of $637,524 from the R & D Tax Incentive program for the 2016 ..Read More

USA Distribution Partner Appointed

Sienna is pleased to announce that leading specialty pathology supply company, StatLab Medical Produ..Read More

Sienna Enters Agreement With UK Distribution Partner

Siena Cancer Diagnostics is pleased to announce the signing of an agreement with HistoCyte Labor..Read More

Sienna Files Additional Patent Application

Sienna is pleased to announce the completion of a further patent application via the Patent Coop..Read More

Sienna Announces Changes To Management Team

Dr Cliff Holloway to stand down as CEO and Managing Director Mr Carl Stubbings appointed Interim..Read More

University of Manchester to Conduct Health Economic Study

A team of pathology and health economics experts at the Manchester Molecular Pathology Innovation Ce..Read More

Johns Hopkins University Begin Follow-On Study

Researchers at the Johns Hopkins University School of Medicine have begun work on a 1000 patient stu..Read More

Appointment of Authorised Representative for EU

In preparation for the registration of their first CE-marked IVD product in the European Union, ..Read More

Sienna Raises $950K In New Capital

Sienna Cancer Diagnostics Limited is pleased to announce that it recently raised approximately $950,..Read More

Clinical Applications Manager Added To Sienna Team

Sienna has appointed Shannon Turnbull as Clinical Applications Manager. Shannon has significant ..Read More

Johns Hopkins Researchers Present At USCAP

Researchers from Johns Hopkins University School of Medicine recently presented a poster outlini..Read More

Dr Donald Robertson Resigns from Board of Directors

Sienna Cancer Diagnostics Ltd announces the resignation of Dr Donald Robertson from the Board. ..Read More

Sienna Appoints Dr John Chiplin Non-Executive Director

Sienna Cancer Diagnostics Ltd is pleased to announce the appointment of Dr John Chiplin to the B..Read More

Sienna Receives R&D Tax Refund

Sienna Cancer Diagnostics Ltd today announced it has received a $682,921 Research & Developm..Read More

Johns Hopkins abstract accepted for presentation at USCAP

In March 2016, researchers from the Johns Hopkins Hospital will present results of a study exami..Read More

Sienna Announces Research Collaboration with Princess Alexandra Hospital and Pathology Queensland

In an expansion of their global network of scientific and clinical research partners, Sienna Can..Read More

Sienna Strengthens its Patent Portfolio

Marking a significant milestone in its commercial growth strategy, Sienna Cancer Diagnostics has..Read More

Dr Holloway Now Permanent CEO

The Sienna board is pleased to announce that Cliff Holloway PhD has accepted the role of permane..Read More

Sienna Enters Research Collaboration With UCLA

In an expansion of their global network of scientific and clinical research partners, Sienna Cancer ..Read More

Team Expansion

In April and May, Sienna expanded its team to add further capability and capacity to drive key initi..Read More

Dr Cliff Holloway Appointed Interim CEO

Sienna today announced that Dr Cliff Holloway has been appointed interim Chief Executive Officer. Dr..Read More

First Product Launch

January 2015 – Marking one of the chief milestones of the Company since inception, Sienna ..Read More

Sienna – On The Move !

Sienna has recently completed a move from the Bio21 building in Parkville which was our home for the..Read More

Sienna Appoints CFO

In November 2014, Sienna made its second senior management appointment during a very productive year..Read More

Sienna Raises $2.1M

Sienna has just completed a $2.1M capital raising through a combination of the exercise of share..Read More

Sienna Lists First ASR Product With FDA

In May 2014 Sienna Cancer Diagnostics announced the successful listing of its lead product, Anti..Read More

Sienna Appoints Inaugural COO

Sienna adds talent and capacity in inaugural COO role Appointment of industry leader to eme..Read More

A$800,000 Grant For Commercialisation

Cancer Diagnostics has been awarded a Federal Government grant to commercialise its innovative t..Read More

Product Manufacture Begins

Sienna has commenced regulatory compliant manufacturing of an analyte specific reagent that binds to..Read More

Grant Funding

Sienna has recently applied for funding as part of the federal government’s Early Stage Commer..Read More

Sign up for updates

Contact Sienna

Sienna Cancer Diagnostics

1 Dalmore Drive Scoresby VIC 3179 Australia

Telephone +61 3 8288 2141 Facsimile +61 3 8288 2059